Condensed Consolidated Statements of Operations (USD $) In Millions, unless otherwise specified	3 Months Ended
	Aug. 31, 2012	Aug. 31, 2011
Net sales	$ 707.4	$ 664.6	[1]
Cost of sales	228.1	215.3
Gross profit	479.3	449.3
Selling, general and administrative expense	296.1	261.6
Research and development expense	35.8	32.0
Amortization	78.4	83.0
Operating income (loss)	69.0	72.7
Interest expense	117.1	125.4
Other (income) expense	37.5	7.2
Other expense, net	154.6	132.6
Income (loss) before income taxes	(85.6)	(59.9)
Benefit from income taxes	(54.1)	(20.7)
Net income (loss)	(31.5)	(39.2)	[2]
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available for sale securities	0.8	4.7
Interest rate swap unrealized gain (loss)	(2.6)	5.9
Foreign currency related gains (losses)	23.2	12.4
Unrecognized actuarial gain (loss) on pension assets		0.1
Other comprehensive income	21.4	23.1
Comprehensive loss	(10.1)	(16.1)
Biomet, Inc.[Member]
Net sales	707.4	664.6
Cost of sales	228.1	215.3
Gross profit	479.3	449.3
Selling, general and administrative expense	296.1	261.6
Research and development expense	35.8	32.0
Amortization	78.4	83.0
Operating income (loss)	69.0	72.7
Interest expense	117.1	125.4
Other (income) expense	37.5	7.2
Other expense, net	154.6	132.6
Income (loss) before income taxes	(85.6)	(59.9)
Benefit from income taxes	(54.1)	(20.7)
Net income (loss)	(31.5)	(39.2)	[2]
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available for sale securities	0.8	4.7
Interest rate swap unrealized gain (loss)	(2.6)	5.9
Foreign currency related gains (losses)	23.2	12.4
Unrecognized actuarial gain (loss) on pension assets		0.1
Other comprehensive income	21.4	23.1
Comprehensive loss	$ (10.1)	$ (16.1)

[1] Certain amounts have been adjusted to conform to the current presentation. The current presentation aligns with how the Company presently manages and markets its products.

[2] Certain amounts have been adjusted to conform to the current presentation.